News
Public · Published
TD Cowen downgrades Boston Scientific to Hold from Buy, lowers price target to $46 from $56
TD Cowen downgraded Boston Scientific to Hold from Buy and lowered its price target to $46 from $56, a 17.9% decrease. The new target implies 7.8% upside from the October 29 close of $42.69.
Published:
Updated:
What happened
TD Cowen downgraded Boston Scientific to Hold from Buy and lowered its price target to $46 from $56, a 17.9% decrease. The new target implies 7.8% upside from the October 29 close of $42.69.
Confirmed
Global impact / market context
A lower price target and a Hold rating can reduce the price investors are willing to pay for Boston Scientific shares, which raises the company's cost of raising money and can make it harder to fund capital spending on medical devices.
Analyst inference
Other recent analyst notes on Boston Scientific show targets from $45 to $52, with a mix of Hold, Buy and Outperform views. TD Cowen's $46 target sits near the low end of that range but still modestly above the recent close.
Analyst inference
What to watch
- Watch whether Boston Scientific reports results or guidance that shift the earnings assumptions behind analyst price targets, since such updates can prompt further rating changes. Confirmed
- TD Cowen may follow the downgrade with updated estimates or commentary explaining what drove the move, so watch for any clarification of its thesis. Proposed
- Watch whether other analysts lower targets toward TD Cowen's $46 level; such convergence would suggest a broader reassessment of expected returns for the stock. Analyst inference
Evidence
- Original source link unavailable